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Abstract
Background: Chronic psychological distress has been linked to shorter telomeres, an indication of accelerated aging. Yet,
little is known about relations of anxiety to telomeres. We examined whether a typically chronic form of anxiety – phobic
anxiety – is related to telomere length.
Methodology/Principal Findings: Relative telomere lengths (RTLs) in peripheral blood leukocytes were measured by
quantitative real-time polymerase chain reaction among 5,243 women (aged 42–69 years) who: were participants in the
Nurses’ Health Study; were controls in prior case-control studies of telomeres and disease, or randomly selected healthy
participants in a cognitive function sub-study; had completed the Crown-Crisp phobic index proximal to blood collection.
Adjusted least-squares mean RTLs (z-scores) were calculated across phobic categories. Higher phobic anxiety was generally
associated with lower RTLs (age-adjusted p-trend=0.09); this association was similar after adjustment for confounders –
paternal age-at-birth, smoking, body mass index (BMI) and physical activity (p-trend=0.15). Notably, a threshold was
identified. Among women with Crown-Crisp,6 points, the multivariable-adjusted least-squares mean RTL z-score=0.02
standard units; however, among the most phobic women (Crown-Crisp$6), the multivariable-adjusted least-squares mean
RTL z-score=20.09 standard units (mean difference=20.10 standard units; p=0.02). The magnitude of this difference was
comparable to that for women 6 years apart in age. Finally, effect modification by BMI, smoking and paternal age was
observed: associations were stronger among highly phobic women with BMI$25 kg/m
2, without smoking history, or born
to fathers aged $40 years.
Conclusions/Significance: In this large, cross-sectional study high phobic anxiety was associated with shorter telomeres.
These results point toward prospective investigations relating anxiety to telomere length change.
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Introduction
Telomeres are repetitive DNA sequences at the ends of
eukaryotic chromosomes that undergo attrition each time a
somatic cell divides. Factors that accelerate attrition include
oxidative stress and inflammation [1,2]. Consequently, average
telomere length (TL) reflects cumulative damage from these
exposures, and is a potential indicator of biological aging [3].
Furthermore, by protecting chromosomal ends, telomeres main-
tain genomic stability [4,5,6]; critically short telomeres lead to
DNA damage (e.g., end-to-end fusion, atypical recombination or
rearrangement) implicated in development of several age-related
diseases [7]. For example, epidemiological studies have reported
associations between shorter TLs and increased risks of cancers
[8,9] and cancer mortality [10], cardiovascular disease [7],
cognitive decline and dementia [11,12]. Because telomere
shortening may underlie many adverse health outcomes in aging,
it is important to identify addressable risk factors.
An emerging literature implicates psychological distress and
mood disorders, both highly prevalent in women, as potential
paths toward accelerated aging [13,14,15,16]. Prior work has
indentified relations of depression to higher levels of inflammatory
mediators and oxidative stress [17]. Although less is known about
its relations to these mechanistic paths, anxiety could also be a risk
factor for morbidity or mortality in aging. In a previous
investigation in the Nurses’ Health Study (NHS), phobic anxiety
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40516was significantly related to higher levels of inflammatory markers
[18] and a elevated risk of sudden cardiac death and fatal coronary
disease [19]. Importantly, phobic anxiety is treatable; thus, any
potential impacts on telomere shortening may be amenable to
prevention through early identification and treatment. However,
there have been few prior investigations of anxiety and telomere
shortening.
Thus, we conducted an examination of the relation of phobic
anxiety to peripheral blood leukocyte TLs (LTLs) in 5,243
participants of the Nurses’ Health Study, who ranged from age
42–69 years (mean=59) when they provided self-reports of phobic
symptoms and blood samples. As phobic anxiety tends to be
chronic – median age at onset is 11 years [20], and course tends to
be highly persistent without treatment [21,22,23] – we hypothe-
sized strong inverse associations between phobic anxiety and LTLs
measured at mid- and later-life.
Methods
Study population
The Nurses’ Health Study (NHS) included 121,700 U.S., female
registered nurses, aged 30 to 55 years at the study’s inception in
1976. Since then, participants have completed biennial mailed
questionnaires updating information on numerous lifestyle factors
and health outcomes; total follow-up exceeds 90%. Details
regarding the NHS and validation of various health exposures
and endpoints have been published previously [24,25,26]. During
the 1988–1990 questionnaire cycle, participants were asked to
complete the Crown-Crisp Index (CCI) of phobic anxiety [27,28].
From 1989 to 1990, 32,826 NHS participants provided blood
samples; details of the blood collection and archival methods have
been described previously [29,30]. The protocols for the NHS, the
NHS blood collection, and the current study were approved by the
Institutional Review Board of Brigham and Women’s Hospital,
Boston, MA, USA. Blood donors gave written informed consent to
having their samples used for research purposes. In addition, all
data was analyzed anonymously.
To determine the final study population, we considered
participants from nested case-control studies of pre-diagnostic
LTLs and incident cancers and cardiovascular disease (CVD), and
from a study of cognitive function (n=9,190) [12,31,32,33].
Although blood collections occurred among both cases and
controls prior to onset of the diseases of interest, we utilized the
most conservative approach and minimized possible bias by
including only controls and the random sample of cognitive study
participants (n=5,415). We excluded women with insufficient
CCI data (i.e., missing .2 items) (n=146) or missing LTL values
(n=26). Thus, the sample for analysis included 5,243 women.
Assessment of phobic anxiety: the Crown-Crisp index
The CCI measures symptoms of phobic anxiety; it has been
validated in psychiatric outpatient settings and found to discrim-
inate patients with general anxiety and phobias from healthy
controls or those with other conditions (i.e., obsessive-compulsive
or depressive) [27,28]. The CCI primarily covers aspects of ‘‘fear’’
disorders, such as panic and agoraphobia. The index features 8
self-rated questions, and total scores range from 0 to 16 points
(higher scores indicate higher anxiety). For those missing data on 1
or 2 items, we chose the more conservative approach of basing the
CCI sum score on only the answered items [34] (i.e., rather than
imputing scores using the mean [19,35]). CCI scores are not
normally distributed, and in keeping with other work [36,37] we
categorized CCI scores into 5 groups: 0 or 1 point (reference
group); 2 points; 3 points; 4 or 5 points; and $6 points (highest
phobic anxiety group; the range of CCI scores in this fifth
group=6–16 points). Of note, the CCI is reliable in the NHS
cohort: the Cronbach coefficient alpha for scores in 1988 was 0.62
– comparable to the coefficient of 0.69 originally reported by
Crown and Crisp among diagnosed patients and controls [28];
item-total correlations were also in the desirable range [38] (0.26–
0.43). Furthermore, identical items were featured on the 2004
NHS questionnaire; the intraclass correlation coefficient (95%
confidence interval [CI]) for the pair of CCI scores in 1988 and
2004 was 0.61 (0.61–0.62), and the Fleiss-Cohen-weighted kappa
(95% CI) for consistency of the 5 phobic categories was 0.56 (0.55–
0.57) – an indication that these measures can reliably represent
long-term phobic anxiety levels.
Measurement of leukocyte telomere length
Genomic DNA was extracted from peripheral blood leukocytes
using the QiAmp (Qiagen) 96-spin blood protocol. Our outcome
measure was relative LTL (RTL) using quantitative real-time
polymerase chain reaction (Q-PCR) [8]. Average RTL was
calculated as the exponentiated ratio of Telomere repeat copy
number to Single gene (36B4) copy number (T/S) corrected for a
reference sample [39]. Laboratory technicians masked to partic-
ipant characteristics assayed each sample in triplicate. Quality
control samples were interspersed on each plate to assess
variability. In all nested case-control studies, coefficients of
variation (CVs) for the telomere and single gene assay were
,4%, and CVs for the exponentiated T/S ratio were ,17%.
Although this assay provides a relative measurement of telomere
length, T/S ratios correlate well with absolute telomere lengths
determined by Southern blot (r=0.82, p,0.0001) [39]. As
expected, significant correlations have been found in the NHS
cohort between shorter telomeres and key predictors: age
(Spearman partial rank correlation coefficient [rs]=20.09,
p,0.0001), smoking pack-years (rs=20.04, p=0.0005) and body
mass index (BMI) (rs=20.04, p=0.0008) [40].
Assessment of covariates
In addition to age-at-blood collection, we considered number of
variables potentially associated with phobic anxiety and telomere
length. Using the biennial questionnaires completed proximal
(1988–1990) to blood collection and a supplemental questionnaire
administered at blood collection, we ascertained factors that have
been related to TLs in the NHS and elsewhere: BMI (kg/m
2);
physical activity (total metabolic equivalent hours of activity per
week [MET-hrs/wk]) [40]; cigarette smoking (pack-years)
[8,41,42]; and paternal age-at-participant’s birth (15–24, 25–29,
30–34, 35–39, $40 years) [43]. Also, we obtained information on
numerous health, social and lifestyle factors: postmenopausal
hormone use, with duration (never or pre-menopausal; past;
current ,5 years or $5 years); oral contraceptive use (ever/never);
anthropometric measures (e.g., waist-hip ratio, waist circumfer-
ence); education (associate’s, bachelor’s, or master’s/doctoral
degree) [44]; race/ethnicity; work status (e.g., employed outside
home, homemaker, retired, etc.) [45]; alcohol intake (grams/day);
daily multivitamin use [46]; medication use, including benzodiaz-
epines (BZDs) (N.B.: regular diazepam use was reported as yes/no
in 1980 and 1982; data on regular antidepressant use was not
available until 1996); and presence/absence of chronic comorbid-
ities (e.g., diabetes, hypertension). Finally, using a validated semi-
quantitative food frequency questionnaire [47] administered in
1990, we assessed dietary factors (e.g., calories, macronutrients, n-
6 and n-3 fatty acids [48], caffeine intake, vitamin intake [46],
antioxidant fruit and vegetable consumption).
Phobic Anxiety and Telomere Length
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The distribution of RTLs varied across batch sets from each
nested case-control study and the cognitive study. Thus, we
computed RTL z-scores within each batch, after calculating the
natural logarithm to improve normality.
To examine potential for confounding, we first examined
univariate associations of the factors described above with phobic
categories and RTL z-scores; variables with significant or
borderline relations to phobic anxiety or RTL were addressed in
preliminary model-building steps. We assessed for threshold
Table 1. Characteristics by phobic anxiety categories (lowest to highest) at blood draw (n=5,243)*.
CHARACTERISTIC Crown-Crisp Index Phobic Anxiety Scores
0o r1 2 3 4o r5 $6
Number of participants 1,782 1,024 816 1,022 599
Median Crown-Crisp phobic index 1.0 2.0 3.0 4.0 7.0
Mean (SD) age (years) 59.3 (6.5) 59.1 (6.6) 59.1 (6.6) 59.4 (6.5) 59.4 (6.5)
Mean (SD) telomere length (z-score) 0.01 (1.00) 0.05 (1.00) 20.01 (1.00) 0.02 (1.01) 20.10 (0.96)
Mean (SD) body mass index (kg/m
2) 25.1 (4.5) 24.9 (4.5) 25.4 (4.4) 25.4 (4.8) 26.0 (5.3)
Mean (SD) alcohol intake (g/day) 5.4 (9.4) 5.6 (9.7) 5.7 (9.6) 5.6 (10.2) 5.4 (10.5)
Mean (SD) physical activity (METs/week) 17.2 (18.3) 15.9 (17.8) 15.9 (18.3) 15.3 (16.5) 13.1 (14.4)
Mean (SD) pack-years of smoking 11.5 (17.5) 13.3 (19.1) 14.0 (19.2) 13.4 (19.1) 14.6 (19.9)
Mean (SD) paternal age at participant’s birth 31.6 (7.2) 31.2 (6.9) 31.4 (6.8) 31.7 (7.3) 31.0 (6.7)
Caucasian race (%) 95.5 96.5 94.9 96.2 95.3
Education (%)
Bachelor’s 22.6 20.5 17.7 18.4 17.5
Master’s/doctoral 12.7 10.5 9.6 7.1 4.8
Multivitamin use (%) 40.2 40.8 40.2 38.1 35.0
Prior benzodiazepine use (%) 4.2 5.6 5.2 7.2 8.2
Ever used oral contraceptives (%) 42.7 42.9 42.2 41.6 36.6
Postmenopausal hormone use (%)
Pre-menopause status, or never 46.0 49.2 44.9 42.6 43.9
Past 15.2 16.2 17.3 20.1 18.5
Current, ,5 years 15.5 14.0 17.4 13.0 14.6
Current, $5 years 23.3 20.6 20.4 24.3 23.0
Asthma, chronic bronchitis, or emphysema (%) 4.7 6.1 5.3 4.9 8.5
Hypertension (%) 27.6 28.5 30.9 32.2 34.2
Diabetes (%) 3.9 4.8 3.6 5.1 6.0
Heart disease (%) 1.7 2.1 1.8 2.6 3.8
Elevated cholesterol (%) 40.2 42.4 43.3 46.5 46.9
Nutrient intakes, in means (SDs)
Total energy (kcal/day) 1746.2 (496.5) 1739.2 (465.7) 1765.4 (485.3) 1774.2 (472.2) 1793.7 (513.1)
Carbohydrate (% of energy) 50.8 (18.9) 50.0 (17.9) 49.4 (17.4) 49.0 (17.0) 48.8 (17.1)
Protein (% of energy) 19.1 (6.7) 18.9 (6.4) 18.6 (6.8) 18.4 (6.4) 18.1 (6.4)
Total fat (% of energy) 30.3 (10.7) 30.8 (11.4) 30.6 (11.4) 30.1 (10.5) 30.3 (11.5)
Saturated fat (% of energy) 10.1 (3.9) 10.3 (4.0) 10.3 (4.1) 10.0 (3.7) 10.2 (4.2)
Mono-unsaturated fat (% of energy) 11.6 (4.4) 11.8 (4.8) 11.8 (4.7) 11.5 (4.2) 11.6 (4.6)
Poly-unsaturated (% of energy) 5.8 (2.3) 5.9 (2.6) 5.8 (2.4) 5.9 (2.6) 5.9 (2.6)
Poly-unsaturated/saturated fat (ratio) 0.61 (0.20) 0.60 (0.20) 0.60 (0.19) 0.61 (0.24) 0.60 (0.21)
Total trans fat (% of energy) 1.39 (0.68) 1.47 (0.87) 1.44 (0.74) 1.42 (0.72) 1.45 (0.80)
Total n-3 fatty acids (% of energy)
{ 0.67 (0.33) 0.66 (0.33) 0.65 (0.45) 0.64 (0.33) 0.63 (0.30)
Fruit and vegetable intake (servings/day) 6.0 (2.6) 5.7 (2.4) 5.9 (2.5) 5.9 (2.6) 5.6 (2.7)
Vitamin D (IU/day) 366.4 (247.0) 364.1 (251.3) 352.6 (251.0) 350.8 (243.9) 341.8 (287.4)
Vitamin E(mg/day) 83.4 (175.8) 104.5 (211.7) 85.7 (190.3) 82.2 (175.9) 79.7 (172.9)
Caffeine (mg/day) 231.4 (205.2) 250.3 (220.1) 243.4 (224.1) 241.8 (215.1) 247.2 (216.4)
*Due to rounding, percentages may not sum to 100.0.
{Combined alpha-linolenic acid and long-chain omega-3 fatty acids (docosahexaenoic and eicosapentaenoic acids).
doi:10.1371/journal.pone.0040516.t001
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treating phobic category as an ordinal predictor.
To examine the association between phobic anxiety and RTLs,
we estimated adjusted least-squares mean RTL z-scores using
three generalized linear models. In the first model, we adjusted for
age-at-blood draw in years. In the second model, we additionally
adjusted for the largest potential contributors to confounding:
BMI, physical activity, pack-years of smoking and paternal age.
Sequentially, we considered other covariates (described above) as
potential confounders, based on prior literature, putative associ-
ations to oxidative stress, or preliminary univariate analyses. As
there were no changes in the estimates with inclusion of these
covariates, they were omitted from the final multivariate model.
Thus, the third model was the primary model and it included:
participant age, paternal age, smoking, BMI and physical activity;
indicator variables were created where covariates had missing
values.
We conducted key secondary analyses to address sensitivity and
to further explore phobic-telomere associations. First, we further
adjusted the primary model for major conditions that are potential
confounders and/or intermediates: hypertension, diabetes, dysli-
pidemia, and CVD. Second, we utilized multiplicative interaction
terms to evaluate whether associations differed by participant age
(,60/$60 years), older parental age (mother ,35/$35 years;
father ,40/$40 years [49]), BMI (18.5–25 vs. $25 kg/m
2),
smoking (ever/never), physical activity (above/below median), or
BZD use (yes/no), as both biology and prior literature support
potential modifying roles [50,51,52]. Third, as some participants
had major comorbidities that could contribute to higher self-
reported anxiety symptom levels as well as shorter telomeres (e.g.,
obstructive airways diseases show strong associations with panic
and anxiety) [53] we conducted separate analyses excluding
women diagnosed with prevalent CVD [54], diabetes [55], or
chronic obstructive airways diseases (asthma, chronic bronchitis or
emphysema) [26,56] prior to or concurrent with blood collection
(total n-excluded=594). Finally, we conducted a separate analysis
to explore relations of individual CCI items to RTLs, adjusting for
age. All statistical analyses were performed using SAS version 9.2
(SAS Institute Inc, Cary, NC). Hypothesis testing was 2-sided, with
a=0.05.
Results
Table 1 shows sample characteristics at blood draw, across
phobic anxiety levels. Women in the highest phobic category were
generally less healthy than those in the lowest category: e.g., higher
phobic anxiety was associated with lower physical activity and
educational attainment, and with higher BMI, smoking pack-
years, and prevalence of hypertension, CVD, obstructive airways
diseases, diabetes, and dyslipidemia. Women with higher phobic
symptoms were less likely to use daily multivitamins or to have
used oral contraceptives, and more likely to have used BZDs.
Regarding diet, slightly higher daily calories, lower energy from
carbohydrates, protein and omega-3 fatty acids, and lower vitamin
D intake were observed among more phobic women; there were
no other consistent differences by phobic anxiety in intake of other
dietary factors.
Higher phobic anxiety was associated with lower age-adjusted
mean RTL z-scores (p-trend=0.09); estimates were similar after
adjustment for paternal age-at-birth, smoking, BMI and physical
activity (p-trend=0.15) (Table 2). However, the phobic anxiety-
RTL association was characterized by a threshold effect (Table 3).
Although women with CCI,6 had adjusted mean RTL z-scores
of 0.02 standard units, those with CCI$6 had mean RTLs of
20.09 standard units (mean difference=20.10 standard units;
p=0.02 for difference in means). When compared to the adjusted
mean RTL z-score for one year of age (20.015 standard units,
p,0.0001), the magnitude of this difference was equivalent to that
observed for women 6 years apart in age.
Further adjustment of the primary multivariate model for major
medical conditions had no influence on results (Table 2). There
were no interactions of high phobic anxiety with participant age,
maternal age, physical activity or prior BZD use. However,
significant interactions were observed by BMI, smoking and
advanced paternal age (APA). Compared with leaner women
(BMI,25 kg/m
2), associations between high phobic anxiety and
lower RTLs were stronger among overweight/obese women
(Figure 1). Mean RTLs were lower overall among smokers, but
there was no association between high phobic anxiety and lower
RTLs; by contrast, the differences in telomere lengths were
striking among never-smokers (Figure 2). The mean difference
(95% CI) in RTL z-scores comparing never-smoking women with
CCI$6 vs. CCI,6 was 20.25 (20.38,20.12) standard units
(p,0.001). There was no interaction between BMI and smoking
or 3-way interaction of phobic anxiety, BMI and smoking. Finally,
a significant phobic anxiety-paternal age interaction was identi-
fied; differences in RTLs were more pronounced among highly
phobic women born to fathers aged $40 years (Figure 3). In the
models excluding participants with prevalent CVD, diabetes or
obstructive airways diseases, estimates were attenuated. For
example, after exclusion of 330 women with CVD or diabetes,
the mean difference in RTLs comparing women with CCI$6 vs.
CCI,6 was 20.09 standard units (p=0.04); with exclusion of an
additional 264 participants with obstructive airways diseases, the
mean difference was 20.07 standard units (p=0.12). Significant
Table 2. Least-squares mean leukocyte telomere length z-scores (standard errors), by phobic anxiety categories.
Crown-Crisp Index Phobic Anxiety Scores
0 o r 1 234 o r 5 $6 P-trend
N 1,782 1,024 816 1,022 599
Age-adjusted 0.01 (0.02) 0.04 (0.03) 20.01 (0.03) 0.02 (0.03) 20.09 (0.04) 0.09
Multivariable-adjusted I
* 0.01 (0.02) 0.04 (0.03) 20.01 (0.03) 0.02 (0.03) 20.09 (0.04) 0.15
Multivariable-adjusted II
{ 0.01 (0.02) 0.04 (0.03) 20.01 (0.03) 0.02 (0.03) 20.09 (0.04) 0.15
*Adjusted for age in years (continuous), paternal age-at-birth (15–24, 25–29, 30–34, 35–39, $40 years), pack-years of smoking (0, 0, to ,20, 20 to ,40, 40+), physical
activity (continuous, MET-hrs/wk), body mass index (continuous, kg/m
2).
{Adjusted for model I variables, plus chronic medical conditions/potential intermediates: hypertension (yes/no), dyslipidemia (yes/no), diabetes (yes/no), cardiovascular
disease (yes/no).
doi:10.1371/journal.pone.0040516.t002
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chronic disease exclusions, but estimates were attenuated: e.g.,
among never-smokers, the mean difference in RTLs comparing
women with CCI$6 vs. CCI,6 was 20.20 standard units
(p=0.004).
In exploratory analyses addressing individual CCI items,
endorsement of the response option that indicated the highest
possible symptom level for a given item was generally associated
with lower age-adjusted mean RTLs (Table S1). However,
estimates appeared strongest for women with highest endorsement
of two items that map to panic and agoraphobia (i.e., compared to
women who did not endorse them at all): ‘‘feel panicky in crowds’’
and ‘‘uneasy traveling on buses or trains’’. Nevertheless, due to the
small number of participants who endorsed the highest symptom
level for each item, estimates were predictably unstable; only one
item, related to agoraphobia (‘‘dislike going out alone’’), was
statistically significant (p=0.047) (Table S1).
Discussion
In this study of 5,243 women, high phobic anxiety was
significantly associated with lower leukocyte telomere lengths. To
aid interpretation of findings [40], we can compare the mean
difference in RTL z-scores associated with high phobic anxiety to
the estimate for women aged one year apart: compared to those
with ,6 points on the Crown-Crisp, women with $6 points had
adjusted RTL z-scores equivalent to 6 years of age. In addition,
effect modification was identified: associations were stronger
among women who were born to older fathers, were heavier or
never smoked. Results were somewhat attenuated after exclusion
of participants with chronic diseases that may act as intermediates
and/or present with higher subjective anxiety and also may be
associated with telomere shortening – suggesting that findings may
be partly explained by influences of phobic anxiety on risk of
development of serious chronic diseases [19]. Finally, exploratory
work indicated that endorsements of higher phobic symptom levels
on individual CCI items were generally related to lower RTLs;
Table 3. Least-squares mean leukocyte telomere length z-scores (standard errors), by high phobic anxiety.
Crown-Crisp Index Phobic Anxiety Scores
,6 $6 P-value
{
N 4,644 599
Age-adjusted 0.02 (0.01) 20.09 (0.04) 0.009
Multivariable-adjusted I
* 0.02 (0.01) 20.09 (0.04) 0.02
Multivariable-adjusted II
{ 0.02 (0.01) 20.09 (0.04) 0.02
*Adjusted for age in years (continuous), paternal age-at-birth (15–24, 25–29, 30–34, 35–39, $40 years), pack-years of smoking (0, 0, to ,20, 20 to ,40, 40+), physical
activity (continuous, MET-hrs/wk), body mass index (continuous, kg/m
2).
{Adjusted for model I variables, plus chronic medical conditions/potential intermediates: hypertension (yes/no), dyslipidemia (yes/no), diabetes (yes/no), cardiovascular
disease (yes/no).
{P-value for test of difference in least-squares means.
doi:10.1371/journal.pone.0040516.t003
Figure 1. Adjusted* least-squares mean leukocyte telomere length z-scores, by phobic anxiety level, stratified by body mass index
(,25 kg/m
2 or $25 kg/m
2). *, Models were adjusted for age in years (continuous), paternal age-at-birth (15–24, 25–29, 30–34, 35–39, $40 years),
pack-years of smoking (0, .0t o,20, 20 to ,40, $40), and physical activity (continuous, MET-hrs/wk). Least squares means and 95% confidence
intervals are shown. N=9 excluded due to missing body mass index.
{, P-value for test of difference in least-squares means.
doi:10.1371/journal.pone.0040516.g001
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agoraphobia. Overall, this study provides a key addition – phobic
anxiety – to an emerging literature that posits mental distress and
disorders as risk factors for accelerated aging [13,14,16,57].
This report is consistent with earlier studies involving well-
characterized samples of patients with diagnosed psychiatric
disorders and controls [14,58,59]. However, there have been few
larger-scale (n.500) population-based studies that specifically
addressed anxiety and telomeres. Kananen et al. [60] measured
RTLs in a sample (aged 30–87 years) of 321 participants with
anxiety diagnosed via structured clinical interviews and 653
controls. Cases included both those with diagnostic manual
criteria-level symptoms and those with core features of anxiety
who did not meet full criteria; the majority of cases, however, met
full criteria for generalized anxiety disorder (GAD), panic disorder,
agoraphobia, and social and other phobia. Although RTLs were
similar among cases and controls overall, cases had significantly
shorter RTLs than controls in the older half of the sample (48–87
years). In contrast, Surtees et al. [61] did not observe significant
differences in RTLs among 4,441 women (aged 41–80 years) with
vs. without either 12-month or lifetime GAD, as diagnosed by
participant self-assessment forms. Discrepant findings may have
Figure 2. Adjusted* least-squares mean telomere length z-scores, by phobic anxiety level, stratified by smoking status (never or
current/past). *, Models were adjusted for age in years (continuous), paternal age-at-birth (15–24, 25–29, 30–34, 35–39, $40 years), body mass
index (continuous, kg/m
2) and physical activity (continuous, MET-hrs/wk). Least squares means and 95% confidence intervals are shown. N=20
excluded due to missing smoking status.
{, P-value for test of difference in least-squares means.
doi:10.1371/journal.pone.0040516.g002
Figure 3. Adjusted* least-squares mean telomere length z-scores, by phobic anxiety level, stratified by paternal age (,40 or $40
years). *, Models were adjusted for age in years (continuous), pack-years of smoking (0, .0t o,20, 20 to ,40, $40), body mass index (continuous,
kg/m
2) and physical activity (continuous, MET-hrs/wk). Least squares means and 95% confidence intervals are shown. N=281 excluded due to
missing paternal age.
{, P-value for test of difference in least-squares means.
doi:10.1371/journal.pone.0040516.g003
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(self-assessment forms vs. structured interviews by clinical raters) or
in the samples (e.g., age, gender, clinical features). For example,
the symptoms of disorders under study by Kananen et al. [60]
(specifically, panic and phobic disorders) have high overlap with
the symptoms captured by the CCI; Surtees and co-workers [61]
considered only GAD. Overall, our finding that lower RTLs were
observed among those with the highest phobic symptoms – i.e.,
potentially a ‘‘caseness’’ level – compared to those below that
threshold, is consistent with work in clinical samples. Nevertheless,
it is not known whether women in the highest phobic symptom
category would necessarily meet criteria [62] for diagnosis of an
anxiety disorder (particularly, panic or agoraphobia), although this
appears plausible.
The findings regarding effect modification of anxiety-telomere
relations are novel and require confirmation/replication. Obesity
may worsen oxidative stress and inflammation [63,64], and
relations of high phobic anxiety and telomere length may be
influenced by body mass or adiposity stores. The findings for
smoking were counter-intuitive. CCI scores were higher among
ever- vs. never-smokers (Wilcoxon rank sum p=0.001), smoking
may trigger oxidative stress/damage [65], and RTLs were lower
overall among smokers in our sample; one might have expected
stronger phobic-telomere associations among smokers. Explana-
tions for this finding include chance as well as putative influences
of nicotine on key inflammatory mediators [66,67] – possibly
providing protection against telomere shortening for highly phobic
smokers that would be absent for equally phobic non-smokers;
however, the latter possibility is purely speculative. Finally,
findings regarding advanced paternal age were intriguing. APA
is associated with longer telomeres [43], but this also allows for
more DNA abnormalities to accumulate and greater DNA
fragmentation [68]. Intriguingly, APA has recently been related
to psychiatric disorders [69,70] and greater externalizing (vs.
internalizing) behaviors in offspring [71]; in our cohort, paternal
age $40 y vs. ,40 y was associated with lower prevalence of high
phobic anxiety (12% vs. 9%, x
2
(df=1)=3.84, p=0.05). Thus, while
explanations remain unclear, one speculative possibility is that
high phobic anxiety might exert an exaggerated impact on
vulnerable DNA, with resulting faster telomere shortening, among
women born to older fathers; alternatively, greater overall
variability in TLs among offspring of older fathers may enhance
ability to detect phobic anxiety-TL relations.
Although the literature is at an early stage, there is biologic
plausibility to support relations of anxiety to shorter telomeres,
particularly via oxidative stress and inflammation. For example, in
a study [72] of 362 healthy adults, higher tension-anxiety symptom
level was correlated with an oxidative DNA damage marker, 8-
hydroxydeoxyguanosine. In a previous NHS investigation [18],
elevated inflammatory markers (tumor necrosis factor-a receptor
II, soluble E-selectin and soluble intercellular adhesion molecule)
were observed among diabetic women with the highest phobic
anxiety (those with CCI$6 were grouped in the same category
with those with CCI=4 or 5) [18]. Similarly, higher scores on the
Spielberger State-Trait Anxiety Inventory were significantly
correlated with elevated C-reactive protein, interleukin-6 and
fibrinogen levels in 853 middle-aged adults [73]. Nevertheless,
despite high prevalence of anxiety [20], few studies have focused
on its relations to oxidative stress and inflammatory biomarkers.
Thus, additional investigation is necessary to delineate potential
impacts of anxiety on aging via these mechanisms.
Strengths of the current study include: use of a validated phobic
anxiety scale; a large, well-characterized sample; and consider-
ation of numerous potential health, lifestyle and socio-demo-
graphic confounders. Also, high phobic symptoms may have been
present among these participants for decades [23] – highlighting
the particular value of relating this exposure to RTLs, which are
markers of cumulative aging. Indeed, a connection between early-
life exposure to adverse mental health environments and
consequences of accelerated aging is an intriguing possibility only
recently examined in the literature [61,74,75].
Potential limitations should be considered. First, the cross-
sectional design precludes establishment of a temporal association
between phobic anxiety and telomere length. For example, the
possibility of bi-directional links has been raised by recent animal
work implicating oxidative stress in development of anxiety [76].
Also, individuals with shorter telomeres may have chronic diseases
that contribute to persistence, or even worsening, of phobic
symptom levels; however, this possibility appears unlikely to
explain results entirely because key findings remained, albeit
attenuated, after excluding individuals diagnosed with major
comorbidities prior to blood collection. Second, RTL was a single
measure, preventing estimation of associations between phobic
anxiety and telomere attrition rate. Third, we lacked specific data
on anxiety onset, duration and/or treatments and, thus, were
unable to incorporate such factors into analyses. Also, we did not
concurrently measure depression (such assessments began in NHS
in 1992); thus, we cannot exclude confounding by depression (e.g.,
comorbidity of depressive disorder among persons with anxiety
disorders has been estimated at 45% [77]). However, a potentially
more likely possibility is that current depression among persons
with high phobic anxiety would represent an intermediate
variable: phobic conditions typically have early-life onset –
decades before median onset of depression [20]; indeed, the
‘‘temporal primacy’’ of anxiety disorders was previously summa-
rized by Kessler [23,78]. Nevertheless, although it seems unlikely
that true confounding by depression would completely explain
results, we cannot make conclusions regarding on the role of
depression in this analysis. Fourth, as in any observational study,
residual confounding is possible. Finally, generalizability is a
potential concern; the Nurses were predominantly (95%) of white
and European race/ethnicity. Because telomere dynamics may
differ among African-Americans and Hispanics [79,80], the
magnitude of associations may not apply to women of other
ethnicities or to men. Nevertheless, basic biologic relations
between anxiety and telomere lengths are likely to hold in all
humans.
In summary, high phobic anxiety may be associated with
shorter leukocyte relative telomere lengths in middle-aged and
older women. Identification of these novel associations invites
further investigation in large-scale prospective studies, with
detailed ascertainment of anxiety and other mental health
variables and repeated measures of telomere length. Furthermore,
because phobic anxiety is usually the temporally primary condition
in comorbidity involving other mental disorders (e.g., depression,
substance abuse) [23], early intervention not only may mitigate
detrimental impacts on aging and but also could avert additional
downstream consequences of accelerated telomere shortening due
to secondary development of other mental disorders or serious
chronic medical conditions.
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